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Background: People with cystic fibrosis (CF) are
susceptible to respiratory infection with Pseudomonas
aeruginosa (PA), which may become chronic if initial
eradication fails. Environmental acquisition and person-
to-person transmission can occur. Respiratory PA
infection is associated with increased mortality and
more hospitalisations. This may cause patients and
families anxiety and lead them to adopt preventive
measures which may be ineffectual and intrusive. It is
not possible to hold a conventional focus group to
explore these issues because people with CF cannot
meet together due to the risk of cross-infection.
Objective: To explore the perceptions of first
respiratory infection with PA in people with CF and
those close to them.
Design: We designed an online survey, to maximise
accessibility and avoid the risk of cross-infection. This
established the respondent’s relationship with CF,
asked 3 open questions about perceptions of PA and a
final question about the prioritisation of research.
Responses were analysed using a structured, iterative
process. We identified keywords, analysed these
incontext and derived key themes.
Setting: Promotion through social media allowed
respondents from any country to participate.
Participants: People with CF and those close to them.
Results: Responses were received from 393 people,
including 266 parents and 97 people with CF. The key
themes were the emotional burden of PA (fear in
particular); the burden of treatment PA entails and the
need for accurate knowledge about PA.
Conclusions: Lack of knowledge and the health
beliefs of individuals may promote fear of infection and
inappropriate avoidance measures. Uncertainty about
the implications of PA infection and the treatment
required may cause anxiety. Healthcare professionals
should provide clear information about how PA might
be acquired and the treatment necessary, making clear
the limitations of current understanding and
acknowledging health beliefs.
INTRODUCTION
Pseudomonas aeruginosa (PA) infection is argu-
ably the most important determinant of
survival in people with cystic ﬁbrosis (CF).
Chronic respiratory infection with PA drives
the cycle of infection, inﬂammation and
lung damage, causing accelerated lung func-
tion decline,1 more frequent exacerbations,2
increased treatment burden and ultimately
accelerated mortality.1
Early respiratory infection with PA can be
eradicated by a number of antibiotic regi-
mens,3 but these all require a signiﬁcant
commitment from patients and families. If
not eradicated, chronic PA management
requires regular inhaled antibiotics and
necessitates an even greater, life-long, treat-
ment burden.4
PA is an environmental organism, widely
found in soil and water. Unfortunately,
neither the speciﬁc source of the infecting
organism nor the mechanism by which infec-
tion occurs are well understood. Cohort seg-
regation by microbiological status was
Strengths and limitations of this study
▪ This is a large qualitative study which gives new
insights into the views of people with cystic
fibrosis (CF) and those close to them, on the
first respiratory infection with Pseudomonas
aeruginosa.
▪ Our online survey, promoted through social
media, allowed wide participation and avoided
the risks of cross-infection.
▪ Our novel methodology, allowed analysis of
responses to open questions, leading to key
‘themes’ identified by participants, which should
help clinicians communicate more effectively
with patients and families.
▪ This was an online survey and so we were
unable to ask further questions to explore the
views of participants in depth.
▪ To encourage the maximum number of
responses, we did not collect information about
the respondent apart from their relationship with
CF.
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adopted in Denmark in the 1980s in an attempt to
prevent new infection5 and has since been implemented
worldwide. While this may reduce acquisition through
cross-infection in the CF centre, respiratory PA infection
may be acquired from the home environment. However,
research has shown that in only a minority of patients is
the newly infecting PA strain genetically identical to one
found in the patient’s home.6 It is also possible that an
infected patient contaminates the home environment,
having acquired infection elsewhere. There is little infor-
mation about acquisition of respiratory PA infection in
the home environment designed to help people with CF
(or parents of affected children) make decisions about
sensible preventive measures. In the absence of clear
information and advice, there is evidence that parents of
children with CF may be very anxious about PA acquisi-
tion and take a variety of measures in an attempt to
prevent infection, which may be intrusive.7 There are
little published data on the views of adults with CF.
Our objective was to understand attitudes towards ﬁrst
respiratory infection with PA among people with CF, the
parents of affected children, extended families and close
friends. A better understanding of these attitudes could
help healthcare professionals communicate information
about respiratory infection with PA more effectively.
METHODS
Data collection
We aimed to investigate the beliefs and perceptions of
people with CF, and those close to them, about respira-
tory infection with PA. We designed a ﬁve-question
survey, based on the experiences of people with CF (see
ﬁgure 1). We used the SurveyMonkey online survey tool
(http://www.surveymonkey.com) to collect responses.
The survey allowed narrative responses of any length
and consisted primarily of open-response questions. The
survey link was distributed through personal Facebook
and Twitter accounts; the UK Cystic Fibrosis Trust
(http://www.cysticﬁbrosis.org.uk); the CF Aware social
media channel (#cfaware) and through CF groups on
Facebook. People completing the survey were invited to
share the link with other interested parties. The survey
was open for responses between 6 and 18 May 2014.
Data were captured automatically by the
SurveyMonkey web service and exported for data hand-
ling and analysis to the N’Vivo qualitative data software
package (QSR International Pty, 2014).
The Research Ethics Committee of the Faculty of
Medicine and Health Sciences, University of
Nottingham, indicated that the research did not require
formal ethical approval.
Data analysis
To reﬂect the digital nature of the data (i.e., collected
online) and the potential for variation in the quality and
quantity of data (ie, respondents may enter as little or
much as they choose), a novel structured, iterative
approach to data analysis was adopted. Keyword (summa-
tive content) analysis8 and keyword-in-context-analysis9
were used to support a broad understanding of the data
set, and a more conventional qualitative, thematic analysis
used to illustrate broad trends and interesting features in
the data. Analysis was iterative insomuch that keyword ana-
lysis informed those words incorporated into the keyword-
in-context-analysis and the keyword-in-context-analysis
informed the thematic analysis.
Keyword analysis
Using the NVivo ‘word frequency’ function, word counts
were performed for each open-response question. Words
of the same derivation (scare, scary, scared, etc) were
linked and short words (3 characters or less) were
excluded. The 25 most frequently used words for each
question were recorded.
Keywords-in-context
Keyword counts were reviewed by the authors to inform
the keywords-in-context analysis. Ten words from each list
of 25 were selected; selection was informed by word
count frequency and by a subjective assessment of word
signiﬁcance, for example, frequently used words such as
lung, think, feel and infection might be excluded at this
point as they offer little substantive insight (ie, they may
simply introduce or link a comment). We made adjust-
ments where words were preceded by a modiﬁer word
(eg, ‘scary’ preceded by ‘not’). Other factors such as
emotive words or words used by one population group in
isolation might lead to less frequently used words being
included at this stage. Keywords-in-context were selected
independently by two authors (SCP and PAL) with dis-
agreements adjudicated by a third author (ARS). Final
lists were agreed by all authors, representing a range of
perspectives on the issue (clinical, personal, research).
The NVivo ‘text search’ and ‘word tree’ display func-
tions were used to isolate selected keywords and demon-
strate their usage. Summaries of word-usage for each
keyword were generated, with a particular concern for
consistency of use and notable usage.
Thematic analysis
Keyword and keyword-in-context analyses may be taken
here as part of the initial ‘analytic effort’ which
Figure 1 Five-question SurveyMonkey survey.
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constitutes a simple thematic analysis.10 Agreement on
the interpretation of keywords-in-context supports the
initial identiﬁcation of ‘themes’ (broad areas of interest)
and ‘codes’ (speciﬁc features, ideas, responses, etc)
which can be applied to the whole data set.
The N’Vivo coding function was used to annotate data
and collect instances where key themes and speciﬁc
codes were manifest in participant responses. Coding
was validated by two authors (SCP and PAL) and further
discussed by all authors to ensure validity and appropri-
ateness of interpretation.
Each data entry was considered independent of prior
keyword analyses and each entry was considered in full
and coded to as many themes/codes as appropriate.
Organisation of coded data within the analytic themes
presents a more clearly contextualised understanding of
how PA is perceived and understood.
RESULTS
Demographics
A total of 393 people responded to the survey—266 had
1 or more children with CF and 97 were people with CF.
Extended family members accounted for 15 responses, 6
were partners/spouses, 5 respondents skipped the ques-
tion and 2 were friends of individuals with CF. Two
people had another relationship to CF; one was a
healthcare worker and one had non-CF bronchiectasis.
Included in the above were three people who identiﬁed
to more than one category: two were people with CF
who also had a sibling with CF; and one had CF and
had a child with CF. The questionnaire did not ask if the
respondent had direct experience of ﬁrst infection with
PA. However, in the free-text responses, 164 of 393
(42%) respondents made direct reference to their
experience of ﬁrst infection with PA. We did not collect
data on respondent’s age, gender or country of
residence.
While most participants completed the survey in
<5 min, some spent as long as 90 min completing it. The
total data set includes 1955 distinct entries and in excess
of 15 000 words.
Keywords, ‘words in context’ and themes
The results at each stage of the analysis, for questions
2–4, are summarised in ﬁgure 2. The questions are given
in the three grey boxes on the left. The most commonly
used words in response to each question are listed in the
ﬁrst column of tables (with the frequencies of each).
The second column of tables lists the 10 most important
words used in response to each question—selected from
a list of 25 according to frequency and signiﬁcance. The
words retained from the frequency analysis to the ‘words
in context’ selection are shaded in blue. The words in
context (from questions 2 to 4) contributed to all of the
three themes identiﬁed and these themes are shown in
the grey boxes on the right.
The most frequently used words, from the ﬁrst stage
of the analysis (question 2), are represented in ﬁgure 3
as a ‘word cloud’.
One word would frequently be used in several contexts.
For example, the word ‘time’ was used to mean:
▸ A point in time. ‘… the ﬁrst time he got
Pseudomonas!’
▸ Time spent on treatment. ‘More time spent on
treatment…’
▸ Time in relation to emotion. ‘Scary time as not sure what
it all meant’
▸ Time meaning the future. ‘…the earlier the infections
start the more damage over time’.
Other words used in a variety of contexts were ‘know’
and ‘life’. From these analyses, three overarching
themes were identiﬁed; the emotional impact of PA, the
burden of treatment and knowledge about PA.
Examples of the codes contributing to each theme are
given in table 1, together with example quotations corre-
sponding to each code.
Theme 1: emotional impact
The emotional impact of respiratory infection with PA
on people with CF, their families and friends is consider-
able. The emotion respondents acknowledged most fre-
quently was fear (152/393 (38.7%) of respondents
reported fear or worry), ranging from simply ‘…
scared…’ to speciﬁc fears, primarily of the negative
health implications, “I get frightened about how much
damage the infection will cause.” Participant 118 (parent).
Fear of recurrent infection remains after successful
eradication, “…it’s always in the back of your mind…are
they going to grow it again?” 115 (parent). Ultimately, the
fear is that PA acquisition will further shorten an already
limited life, “A stage closer to death,” 388 (parent). For
some, the fear itself is debilitating, “My experience in
relation to lung function was insigniﬁcant, however, the
psychological effect was all-consuming. I even had to
take time off work to get my head around it. The magni-
tude & signiﬁcance was just too scary!” 57 (patient). The
acquisition of PA may be a devastating blow—there is a
sense of loss associated with the perceived change in
health status, “…you think your child is invincible with
mild CF until the ﬁrst pseudomonas call.” 212 (parent).
Patients, and particularly parents, go to great lengths
to avoid PA, “…we don’t allow animals in our house, we
don’t visit friends’ houses with pets. We don’t do horse
riding. We are incredibly picky about where she uses
swimming pools…” 3 (parent). Acquisition is felt to be
inevitable, but parents still feel that they must take active
preventive measures, “Terrifying bacteria we spend our
lives trying to avoid, yet accept it is probably inevit-
able…” 165 (parent). Measures taken to avoid PA may
have a detrimental effect on development, particularly if
it means a child missing out on school or time with
friends, “…my son aged 7 is paranoid about it and
misses out in so much activity for fear of getting it,” 111
(parent). For adolescents and adults, the health
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uncertainty affects their ability to make plans, “It means
worrying about letting people down,” 367 (patient).
First infection with PA marks a turning point in
people’s relationship with CF. For many, it is, “…a slap
in the face that CF is real.” 278 (parent). Prior to PA
infection people are more able to deny the seriousness
of the condition. “I had always used it as a benchmark,
i.e. ‘I’ll be okay because I’ve never had Pseudo’,” 281
(patient). Acquisition therefore, causes a re-evaluation of
general health and disease trajectory, psychologically
marking a transition to ill-health.
Theme 2: treatment burden
The additional treatment required after respiratory PA
infection causes signiﬁcant inconvenience to patients
and their families. In particular, the introduction of
extra nebulised treatment was commonly cited as a
major impact of ﬁrst infection, “…I now have an extra
nebuliser or inhaler to do twice a day for the rest of my
life—which means another hour of every day lost to
treatments,” 163 (patient). Additional time spent on treat-
ment conﬂicts with other activities for the person with
CF which may worsen social isolation, “It means having
Figure 2 Flow diagram of qualitative analysis for research questions 2–4, showing progress through word frequency, ‘words in
context’ and themes. Words retained from frequency analysis to ‘words in context’ are shaded in blue. The words in context (from
questions 2–4) contributed to all of the three themes identified.
Figure 3 The most commonly
used words in response to
question 2.
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to do more treatments every day, particularly nebulised
antibiotics which are time consuming and restrict your
freedom to travel and work. This also marks you out as
being different from peers which can be hard to deal
with psychologically,” 367 (patient).
Many respondents mentioned the difﬁculties posed by
more frequent hospital admissions, which followed the
acquisition of PA. For the person with CF admission
means absence from school or work, “…3–4 hospital
admissions a year which has signiﬁcantly affected my
ability to attend school, uni and work,” 283 (patient). For
parents, an admission similarly leads to time off work to
support their child, “…rearranging work life etc. for hos-
pitalization if required.” 195 (parent).
Nebulised drugs and hospital admissions are frequently
novel treatment modalities after PA acquisition. For some
families, the therapy itself is stressful, “Now J needs nebs,
our day is ﬁlled with resistance, arguing and tension
because it’s another thing he doesn’t want to do…” 113
(parent). Treatment may be more invasive, particularly
where the patient requires an intravenous line—a pro-
cedure which in some cases requires a general anaes-
thetic, “He had to have I.V’s for the ﬁrst time and he was
put under general anaesthetic.” 261 (parent). Some
parents expressed concerns about the ‘strength’ of treat-
ment needed after PA acquisition, particularly where
their child was young, “The start of lots of extra powerful
drugs that can cause lots of harm to the body of my son,”
217 (parent). Others reﬂected on side effects, such as skin
photosensitivity with ciproﬂoxacin, “Being on cipro isn’t
so bad in winter but is tough in summer.” 324 (parent).
Theme 3: knowledge
Knowledge about PA is beneﬁcial and detrimental. Prior
to respiratory infection with PA, many patients and
parents are aware of the organism and the potential
health consequences, and this knowledge may induce
fear, “We panicked as only heard bad things about the
infection,” 33 (parent). There is an assumption that PA
infection will immediately lead to severe health decline
or even death, “I thought I was going to die very quickly
after getting it,” 16 (patient). Thus, prior, incomplete,
understanding may worsen fear, “…even if you have suc-
cessfully eradicated it, it is guaranteed you will get it
again,” 156 (parent), and promote unrealistic avoidance
measures, “…have turned into a clean freak to keep it
away to the best of my ability…” 177 (parent).
Others have very little prior knowledge about PA, “Not
something I had been pre-warned about or even read
about,” 249 (parent). Some perceived that there was
insufﬁcient support from the healthcare team, “We were
left with no support…It was awful and desperately worry-
ing until the next clinic appointment…” 235 (parent).
Others, however, found that gaining greater understand-
ing of the potential for eradication helped, “Was worried
at ﬁrst but I know it’s treatable,” 242 (parent). The knowl-
edge gained by experience of living with PA can be
reassuring, “…10 years on I can look back and say it
didn’t cause the problems I thought it would,” 387
(parent). Others found discovery of acquisition beneﬁ-
cial, “…the earlier you know the harder you can hit it
with treatment,” 364 (patient).
Lack of clear advice about PA acquisition makes some
parents restrict their child’s activities, “…this has made
me pretty paranoid about everything as pseudo is every-
where and whilst I know it shouldn’t, as life is for living
etc, it does make me stop my little boy from doing a few
things due to the risks,” 151 (parent). Parents described
replacing kitchens or bathrooms, or even moving house,
due to concerns about the source of PA.
Importance of PA for future research
Question 5 asked respondents to rate, on an ordinal scale,
“How important do you think it is to develop more
Table 1 Summary of thematic analysis
Theme Code Example of data
Emotional
impact
Fear “My experience in relation to lung function was insignificant, however, the psychological
effect was all-consuming. I even had to take time off work to get my head around it. The
magnitude & significance was just too scary!” (patient)
Resignation “Terrifying bacteria we spend our lives trying to avoid, yet accept it is probably
inevitable…” (parent)
Realisation “[pseudomonas is]…a slap in the face that CF is real” (parent)
Treatment
burden
Restricting “It means having to do more treatments every day, particularly nebulised antibiotics which
are time consuming and restrict your freedom to travel and work. This also marks you out
as being different from peers which can be hard to deal with psychologically” (patient)
Stressful “Now J needs nebs, our day is filled with resistance, arguing and tension because it’s
another thing he doesn’t want to do…” (parent)




“Not something I had been pre-warned about or even read about” (parent)
Incomplete “I thought I was going to die very quickly after getting it” (patient)
Beneficial “…the earlier you know the harder you can hit it with treatment” (patient)
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effective ways to deal with P. aeruginosa?” The scale ranged
in ﬁve steps from ‘totally unimportant’ to ‘top priority/
urgent’. The answer was given as ‘top priority/urgent’ by
314 of 393 (80.0%) respondents.
DISCUSSION
This study collected the views of a large number of
people with CF, the parents of affected children,
extended families and close friends, about ﬁrst respira-
tory infection with PA. We used a novel web-based survey
which was accessible to participants internationally.
There was active promotion of the survey from within
the CF community, since the survey author is a person
with CF. We identiﬁed three prominent themes; emo-
tional impact, treatment burden and knowledge. These
themes should inform CF care teams, allowing them to
provide more effective support for patients and those
close to them.
Our study echoes the ﬁndings of previous work by
Ullrich et al,7 who interviewed the parents of 21 children
with CF about their attitudes to PA. They identiﬁed a
spectrum of attitudes ranging from ‘bacterium-focused’
at one extreme to ‘child-focused’ at the other. Parents
who were ‘bacterium-focused’ described taking measures
to reduce their child’s exposure to PA, both indoors and
out, which could be restrictive and intrusive. A question-
naire survey from the same investigators11 described
data from 130 parents from 10 German CF centres.
Responses revealed that parents had incorrect beliefs
about PA. They undertook an average of 11 ‘hygienic
measures’, inside (eg, the affected child would use a dif-
ferent toothbrush morning and evening) and outside
the home (the parents did not use air conditioning in
the car). Parents felt stressed by the prospect of PA
infection and the hygienic measures they believed would
prevent this. Infection control guidelines in the USA12
give detailed advice on preventing cross-infection in the
hospital setting but make few recommendations for
infection control at home. European guidelines13 are
restricted to infection control in CF centres. In the
absence of speciﬁc guidelines, there is some evidence
that physicians advocate a variety of preventive measures
which may lead to confusion and uncertainty among
people affected by CF.14
Previous qualitative work with adults with CF and
parents of affected children has identiﬁed themes such
as ‘from uncertainty to certainty’ and a desire for a
‘demanding yet normal life’.15 These themes relate
closely to the themes of ‘knowledge’ and ‘treatment
burden’ which we identiﬁed in our study. The theme of
‘treatment burden’ is also prominent in qualitative work,
conducted with CF adults, who discussed their nebulised
medication—an essential component both of PA eradi-
cation and long-term suppressive therapy for PA.16 This
work describes ‘intentional non-adherence’ when adult
CF patients must balance the demands of busy lives with
the requirement for time-consuming therapy. Indepth
interviews with CF adults have shown that many experi-
ence emotional symptoms such as frustration, sadness/
depression, irritability, worry and difﬁculty sleeping.17
These symptoms are likely to be exacerbated by the
anticipation or occurrence of signiﬁcant life events, such
as respiratory infection with PA. Relatives and others
who are close to people with CF may adopt the role of
‘lay carers’, many of whom contributed to our qualitative
survey. Previous qualitative work has shown that the
information needs of ‘lay carers’ may be overlooked by
CF teams.18
Qualitative researchers often use a semistructured
interview or focus group methodology whereby indepth
interviews are conducted with a small number of partici-
pants, until no new themes emerge (data saturation).19
These interviews allow supplementary questions (which
are reﬁned in successive interviews) to enrich the data
collected. A focus group approach was not open to us
because of the risks of cross-infection that would entail.
While we were unable to develop and ask supplementary
questions, our online format allowed us to include many
more participants. Similarly, to encourage the maximum
number of responses, we did not collect information
about the respondent apart from their relationship with
CF (eg country of residence and gender were not col-
lected). The large number of respondents increased the
reach of our research and the generalisability of our
ﬁndings.
It is not yet possible for CF teams to provide certainty
about the risks for acquisition of PA, without consider-
able further research. Such research was strongly sup-
ported by respondents to our survey. CF teams should
support patients (and those close to them) in addressing
fear of PA acquisition, through proposing only those pre-
ventive measures supported by good evidence and by
acknowledging the health beliefs of patients and fam-
ilies. Further research should also explore the informa-
tion needs of people with CF and compare these with
the needs to parents, so that information can be tailored
appropriately. Our data indicate that ﬁrst acquisition of
PA marks a turning point in the relationship with CF for
many patients and parents. CF teams should therefore
ensure that sufﬁcient time is available for discussion,
when a new infection occurs, as well as providing clear
information about treatment and the likelihood of suc-
cessful eradication.
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